Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers
2010

SMAD3 and Breast Cancer Risk in BRCA2 Mutation Carriers

Sample size: 4724 publication Evidence: moderate

Author Information

Author(s): Walker Logan C, Fredericksen Zachary S, Wang Xianshu, Tarrell Robert, Pankratz Vernon S, Lindor Noralane M, Beesley Jonathan, Healey Sue, Chen Xiaoqing, Stoppa-Lyonnet Dominique, Tirapo Carole, Giraud Sophie, Mazoyer Sylvie, Muller Danièle, Fricker Jean-Pierre, Delnatte Capucine, Schmutzler Rita K, Wappenschmidt Barbara, Engel Christoph, Schönbuchner Ines, Deissler Helmut, Meindl Alfons, Hogervorst Frans B, Verheus Martijn, Hooning Maartje J, van den Ouweland Ans MW, Nelen Marcel R, Ausems Margreet, Aalfs Cora M, van Asperen Christi J, Devilee Peter, Gerrits Monique M, Waisfisz Quinten, Sinilnikova Olga M, McGuffog Lesley, Antoniou Antonis C, Chenevix-Trench Georgia, Spurdle Amanda B, Couch Fergus J

Primary Institution: Queensland Institute of Medical Research

Hypothesis

Does the SMAD3 gene modify breast cancer risk in BRCA2 mutation carriers?

Conclusion

The SMAD3 gene may contribute to increased breast cancer risk in BRCA2 mutation carriers.

Supporting Evidence

  • Five SNPs in candidate genes showed evidence of association with breast cancer risk.
  • The minor alleles of two SNPs at the SMAD3 locus were associated with increased breast cancer risk for BRCA2 mutation carriers.
  • Relative risk estimates indicated that the minor alleles of the SNPs were linked to higher breast cancer risk.

Takeaway

This study found that a gene called SMAD3 might make women with BRCA2 mutations more likely to get breast cancer.

Methodology

The study genotyped 24 SNPs in a cohort of up to 4,724 BRCA1 and 2,693 BRCA2 female mutation carriers to assess their association with breast cancer risk.

Potential Biases

There may be risks of bias due to the selection criteria for study participants.

Limitations

The study is limited by the highly-selected nature of subjects and potential survival bias.

Participant Demographics

Participants included female BRCA1 and BRCA2 mutation carriers aged 18 years or older from 15 study groups across multiple countries.

Statistical Information

P-Value

0.004 for rs7166081; 0.018 for rs3825977

Confidence Interval

1.07 to 1.45 for rs7166081; 1.03 to 1.40 for rs3825977

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/bcr2785

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication